A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia
Open Access
Abstract
Background: The high burden of extended-spectrum beta-lactamase-producing (ESBL)-producing Enterobacterales worldwide, especially in the densely populated South East Asia poses a significant threat to the global transmission of antibiotic resistance. Molecular surveillance of ESBL-producing pathogens in this region is vital for understanding the local epidemiology, informing treatment choices, and addressing the regional and global implications of antibiotic resistance. Methods: Therefore, an inventory surveillance of the ESBL-Escherichia coli (ESBL-EC) isolates responsible for infections in Malaysian hospitals was conducted. Additionally, the in vitro efficacy of flomoxef and other established antibiotics against ESBL-EC was evaluated. Results: A total of 127 non-repetitive ESBL-EC strains isolated from clinical samples were collected during a multicentre study performed in five representative Malaysian hospitals. Of all the isolates, 33.9% were isolated from surgical site infections and 85.8% were hospital-acquired infections. High rates of resistance to cefotaxime (100%), cefepime (100%), aztreonam (100%) and trimethoprim-sulfamethoxazole (100%) were observed based on the broth microdilution test. Carbapenems remained the most effective antibiotics against the ESBL-EC, followed by flomoxef. Antibiotic resistance genes were identified by PCR. The blaCTX-M-1 was the most prevalent ESBL gene, with 28 isolates (22%) harbouring blaCTX-M-1 only, 27 isolates (21.3%) co-harbouring blaCTX-M-1 and blaTEM, and ten isolates (7.9%) co-harbouring blaCTX-M-1, blaTEM and blaSHV. A generalised linear model showed significant antibacterial activity of imipenem against different types of infection. Besides carbapenems, this study also demonstrated a satisfactory antibacterial activity of flomoxef (81.9%) on ESBL-EC, regardless of the types of ESBL genes.Keywords
Funding Information
- Ministry of Higher Education (Malaysia), Transdisciplinary Research Grant Scheme, TRGS (TR001B-2020)
- Shionogi Singapore Pte. Ltd (IF015-2018)
This publication has 39 references indexed in Scilit:
- Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteriaAntimicrobial Resistance & Infection Control, 2014
- Ethnic Disparities in Metabolic Syndrome in Malaysia: An Analysis by Risk FactorsMetabolic Syndrome and Related Disorders, 2011
- Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coliAntimicrobial Agents and Chemotherapy, 2010
- Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2010
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008
- Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 β-lactamasesJournal of Antimicrobial Chemotherapy, 2007
- Dissemination of CTX-M-Type β-Lactamases among Clinical Isolates of Enterobacteriaceae in Paris, FranceAntimicrobial Agents and Chemotherapy, 2004
- The meaning of the development of flomoxef and clinical experience in JapanInfection, 1991
- More extended-spectrum beta-lactamasesAntimicrobial Agents and Chemotherapy, 1991
- Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic.The Journal of Antibiotics, 1985